Reportlinker Adds The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues

NEW YORK, March 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues

http://www.reportlinker.com/p0184375/The-Future-of-Dermatology-Therapeutics-Analysis-and-Market-Forecasts-to-2016---Increasing-Prescription-Rate-to-Drive-Revenues.html

The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues

Summary

GBI Research has released its research - "The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues". The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the dermatology therapeutics market from 2001 to 2009, forecast forward to 2016

- Analysis of the leading therapeutic segments. These include Acne, Psoriasis, Dermatitis, Rosacea and Skin diseases.

- Analysis of the dermatology therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the dermatology therapeutics market including market size, annual cost of therapy, and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, GlaxoSmithKline, Leo Pharma, Sanofi-Aventis, Genentech, Novartis AG, Johnson & Johnson, Galderma Pharma SA, and Merck & Co, Inc.

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global dermatology therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 10

2 Global Dermatology Therapeutics Market: Scope of Research 12

2.1 Introduction 12

2.2 GBI Research Report Guidance 12

3 Global Dermatology Therapeutics Market: Market Characterization 13

3.1 Market Forecasts 13

3.2 Usage Patterns 14

3.2.1 Diseased Population 14

3.2.2 Treatment Seeking Population 15

3.2.3 Diagnosis Population 16

3.2.4 Prescription Population 17

3.2.5 Therapy Usage Patterns 18

3.2.6 Geographical Distribution 19

4 Global Dermatology Therapeutics Market: US Market 20

4.1 Market Overview 20

4.2 Market Forecasts 20

4.3 Usage Patterns 21

4.3.1 Diseased Population 21

4.3.2 Treatment Seeking Population 22

4.3.3 Diagnosis Population 23

4.3.4 Prescription Population 24

4.3.5 Therapy Usage Patterns 25

5 Global Dermatology Therapeutics Market: European Market 27

5.1 Market Overview 27

5.2 Market Forecasts 27

5.3 Usage Patterns 28

5.3.1 Diseased Population 28

5.3.2 Treatment Seeking Population 29

5.3.3 Diagnosis Population 30

5.3.4 Prescription Population 31

5.3.5 Therapy Usage Patterns 32

6 Global Dermatology Therapeutics Market : Japan Market 34

6.1 Market Overview 34

6.2 Market Forecasts 34

6.3 Usage Patterns 35

6.3.1 Diseased Population 35

6.3.2 Treatment Seeking Population 36

6.3.3 Diagnosis Population 37

6.3.4 Prescription Population 38

6.3.5 Therapy Usage Patterns 39

7 Global Psoriasis Therapeutics Market 41

7.1 Market Overview 41

7.2 Market Forecasts 42

7.3 Average Cost of Therapy 43

7.4 Usage Patterns 44

7.4.1 Diseased Population 44

7.4.2 Treatment Seeking Population 45

7.4.3 Diagnosis Population 46

7.4.4 Prescription Population 47

7.4.5 Therapy Usage Patterns 48

7.5 Product Analysis 50

7.5.1 Enbrel (etanercept) 50

7.5.2 Humira (adalimumab) 50

7.5.3 Amevive (alefacept) 51

7.5.4 Remicade (infliximab) 51

7.5.5 Stelara (ustekinumab, CNTO1275) 51

7.5.6 Clobex (clobetasol propionate) 51

7.5.7 Tazorac (tazarotene, Avage) 51

7.5.8 Dovonex (calcipotriene) 52

7.5.9 Neoral (cyclosporine) 52

7.6 Drug Pipeline Analysis 52

7.6.1 Psoriasis Therapeutics – Phase III Clinical Pipeline 53

7.6.2 Psoriasis Therapeutics – Phase II Clinical Pipeline 54

8 Global Atopic Dermatitis Therapeutics Market 57

8.1 Market Overview 57

8.2 Market Forecasts 57

8.3 Average Cost of Therapy 59

8.4 Usage Patterns 60

8.4.1 Diseased Population 60

8.4.2 Treatment Seeking Population 61

8.4.3 Diagnosis Population 62

8.4.4 Prescription Population 63

8.4.5 Therapy Usage Patterns 64

8.5 Product Analysis 65

8.5.1 Protopic (Tacrolimus) 65

8.5.2 Elidel (Pimecrolimus) 66

8.5.3 MimyX 66

8.5.4 Atopiclair 66

8.5.5 Topical Corticosteroids 66

8.6 Drug Pipeline Analysis 66

9 Global Acne Therapeutics Market 71

9.1 Market Overview 71

9.2 Market Forecasts 71

9.3 Usage Patterns 73

9.3.1 Diseased Population 73

9.3.2 Treatment Seeking Population 74

9.3.3 Diagnosis Population 75

9.3.4 Prescription Population 76

9.3.5 Therapy Usage Patterns 77

9.4 Product Analysis 78

9.5 Drug Pipeline Analysis 78

10 Global Rosacea Disease Therapeutics Market 84

10.1 Market Overview 84

10.2 Market Forecasts 84

10.3 Average Cost of Therapy 85

10.4 Usage Patterns 86

10.4.1 Diseased Population 86

10.4.2 Treatment Seeking Population 87

10.4.3 Diagnosis Population 88

10.4.4 Prescription Population 89

10.4.5 Therapy Usage Patterns 90

10.5 Product Analysis 91

10.6 Drug Pipeline Analysis 92

11 Global Dermatology Therapeutics Market: Market Drivers and Restraints 95

11.1 Market Drivers 95

11.1.1 Steady Increase in the Elderly Population 95

11.1.2 Stable Increase in Incidence Rates for Dermatology Diseases 96

11.1.3 Increase in Awareness Levels of Disease Progression and Etiology 96

11.2 Market Restraints 96

11.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers 96

11.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic drugs 96

12 Global Dermatology Therapeutics Market : Key Market Trends 97

13 Global Dermatology Therapeutics Market: Competitive Landscape 98

13.1 Overview 98

13.2 Market Share Analysis 98

13.3 Competitive Profiling 98

13.3.1 GlaxoSmithKline plc (GSK) 98

13.3.2 Johnson & Johnson 100

13.3.3 Bayer AG 102

13.3.4 Merck & Co., Inc 103

13.3.5 Novartis AG 105

13.3.6 Sanofi-Aventis 106

13.3.7 LEO Pharma A/S 107

13.3.8 F. Hoffmann-La Roche Ltd 108

13.3.9 L'Oreal 109

13.3.10 Galderma S.A. 109

13.3.11 Nestle S.A. 110

14 Dermatology Therapeutics Market: Pipeline Analysis 112

14.1 Pipeline I 113

14.2 Pipeline II 118

14.3 Pipeline III 133

14.4 Promising Drugs under Clinical Development 143

14.4.1 Voclosporin (LX211, LUVENIQ, ISA-247) 143

14.4.2 ABT-874 (J-695, Briakinumab) 143

14.4.3 CF-101 144

14.4.4 Orencia (abatacept, CTLA4-Ig, BMS-188667) 144

14.4.5 Cimzia (CDP870 certolizumab pegol) 144

14.4.6 Apremilast (CC10004, ACR20) 144

14.4.7 INCB18424 144

14.4.8 PH-10 144

14.4.9 Hivenyl 144

14.4.10 TF002 145

15 Global Dermatology Therapeutics Market: M&A Landscape 146

15.1 Mergers and Acquisitions 146

15.1.1 Overview 146

15.2 Licensing Agreements 146

15.2.1 Overview 146

15.2.2 Drug Discovery & Preclinical 149

15.2.3 Phase I 150

15.2.4 Phase II 152

15.2.5 Phase III 153

15.2.6 Approved Stage 154

16 Global Dermatology Therapeutics Market : Appendix 159

16.1 Market Definitions 159

16.2 Abbreviations 159

16.3 Research Methodology 160

16.3.1 Coverage 160

16.3.2 Secondary Research 161

16.3.3 Primary Research 161

16.3.4 Forecasts 162

16.3.5 Expert Panel Validation 164

16.4 Contact Us 165

16.5 Disclaimer 165

1.1 List of Tables

Table 1: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009 13

Table 2: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 13

Table 3: Dermatology Therapeutics Market, Global, Diseased Population, 2001-2009 14

Table 4: Dermatology Therapeutics Market, Global, Diseased Population, 2009-2016 14

Table 5: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 15

Table 6: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 15

Table 7: Dermatology Therapeutics Market, Global, Diagnosis Population, 2001-2009 16

Table 8: Dermatology Therapeutics Market, Global, Diagnosis Population, 2009-2016 16

Table 9: Dermatology Therapeutics Market, Global, Prescription Population, 2001-2009 17

Table 10: Dermatology Therapeutics Market, Global, Prescription Population, 2009-2016 17

Table 11: Dermatology Therapeutics Market, Global, Usage Patterns, 2001-2009 18

Table 12: Dermatology Therapeutics Market, Global, Usage Patterns, 2009-2016 19

Table 13: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2001-2009 20

Table 14: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2009-2016 20

Table 15: Dermatology Therapeutics Market, The US, Diseased Population, 2001-2009 21

Table 16: Dermatology Therapeutics Market, The US, Diseased Population, 2009-2016 21

Table 17: Dermatology Therapeutics Market, The US, Treatment Seeking Population, 2001-2009 22

Table 18: Dermatology Therapeutics Market, The US, Treatment Seeking Population, 2009-2016 22

Table 19: Dermatology Therapeutics Market, The US, Diagnosis Population, 2001-2009 23

Table 20: Dermatology Therapeutics Market, The US, Diagnosis Population, 2009-2016 23

Table 21: Dermatology Therapeutics Market, The US, Prescription Population, 2001-2009 24

Table 22: Dermatology Therapeutics Market, The US, Prescription Population, 2009-2016 24

Table 23: Dermatology Therapeutics Market, The US, Usage Patterns, 2001-2009 25

Table 24: Dermatology Therapeutics Market, The US, Usage Patterns, 2009-2016 26

Table 25: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2001-2009 27

Table 26: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2009-2016 27

Table 27: Dermatology Therapeutics Market, Europe, Diseased Population, 2001-2009 28

Table 28: Dermatology Therapeutics Market, Europe, Diseased Population, 2009-2016 28

Table 29: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2001-2009 29

Table 30: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2009-2016 29

Table 31: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2001-2009 30

Table 32: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2009-2016 30

Table 33: Dermatology Therapeutics Market, Europe, Prescription Population, 2001-2009 31

Table 34: Dermatology Therapeutics Market, Europe, Prescription Population, 2009-2016 31

Table 35: Dermatology Therapeutics Market, Europe, Usage Patterns, 2001-2009 32

Table 36: Dermatology Therapeutics Market, Europe, Usage Patterns, 2009-2016 33

Table 37: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2001-2009 34

Table 38: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2009-2016 34

Table 39: Dermatology Therapeutics Market, Japan, Diseased Population, 2001-2009 35

Table 40: Dermatology Therapeutics Market, Japan, Diseased Population, 2009-2016 35

Table 41: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2001-2009 36

Table 42: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2009-2016 36

Table 43: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2001-2009 37

Table 44: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2009-2016 37

Table 45: Dermatology Therapeutics Market, Japan, Prescription Population, 2001-2009 38

Table 46: Dermatology Therapeutics Market, Japan, Prescription Population, 2009-2016 38

Table 47: Dermatology Therapeutics Market, Japan, Usage Patterns, 2001-2009 39

Table 48: Dermatology Therapeutics Market, Japan, Usage Patterns, 2009-2016 40

Table 49: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009 42

Table 50: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 42

Table 51: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2009 43

Table 52: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($) 2009-2016 43

Table 53: Psoriasis Therapeutics Market, Global, Diseased Population, 2001-2009 44

Table 54: Psoriasis Therapeutics Market, Global, Diseased Population, 2009-2016 45

Table 55: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 45

Table 56: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 46

Table 57: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2001-2009 47

Table 58: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2009-2016 47

Table 59: Psoriasis Therapeutics Market, Global, Prescription Population, 2001-2009 48

Table 60: Psoriasis Therapeutics Market, Global, Prescription Population, 2009-2016 48

Table 61: Psoriasis Therapeutics Market, Global, Usage Patterns, 2001-2009 49

Table 62: Psoriasis Therapeutics Market, Global, Usage Patterns, 2009-2016 49

Table 63: Psoriasis Therapeutics – Phase III Clinical Pipeline, 2009 53

Table 64: Psoriasis Therapeutics – Phase II Clinical Pipeline, 2009 54

Table 65: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009 58

Table 66: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 58

Table 67: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2001-2009 59

Table 68: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2009-2016 59

Table 69: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2001-2009 60

Table 70: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2009-2016 60

Table 71: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 61

Table 72: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 61

Table 73: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2001-2009 62

Table 74: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2009-2016 62

Table 75: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2001-2009 63

Table 76: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2009-2016 63

Table 77: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2001-2009 64

Table 78: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2009-2016 65

Table 79: Atopic Dermatitis Therapeutics – Phase III Clinical Pipeline, 2010 67

Table 80: Atopic Dermatitis Therapeutics – Phase II Clinical Pipeline, 2010 68

Table 81: Atopic Dermatitis Therapeutics – Phase I Clinical Pipeline, 2010 69

Table 82: Atopic Dermatitis Therapeutics – Pre-Clinical Pipeline, 2010 69

Table 83: Atopic Dermatitis Therapeutics – Discovery Pipeline, 2010 70

Table 84: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009 72

Table 85: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 72

Table 86: Acne Therapeutics Market, Global, Diseased Population, 2001-2009 73

Table 87: Acne Therapeutics Market, Global, Diseased Population, 2009-2016 73

Table 88: Acne Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 74

Table 89: Acne Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 74

Table 90: Acne Therapeutics Market, Global, Diagnosis Population, 2001-2009 75

Table 91: Acne Therapeutics Market, Global, Diagnosis Population, 2009-2016 75

Table 92: Acne Therapeutics Market, Global, Prescription Population, 2001-2009 76

Table 93: Acne Therapeutics Market, Global, Prescription Population, 2009-2016 76

Table 94: Acne Therapeutics Market, Global, Usage Patterns, 2001-2009 77

Table 95: Acne Therapeutics Market, Global, Usage Patterns, 2009-2016 78

Table 96: Acne Therapeutics Market , Clinical Pipeline , 2009 79

Table 97: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009 84

Table 98: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 85

Table 99: Rosacea Therapeutics Market, Global, Average Cost of Therapy, ($) 2001-2009 85

Table 100: Rosacea Therapeutics Market, Global, Average Cost of Therapy ($), 2009-2016 85

Table 101: Rosacea Therapeutics Market, Global, Diseased Population, 2001-2009 87

Table 102: Rosacea Therapeutics Market, Global, Diseased Population, 2009-2016 87

Table 103: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 88

Table 104: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 88

Table 105: Rosacea Therapeutics Market, Global, Diagnosis Population, 2001-2009 89

Table 106: Rosacea Therapeutics Market, Global, Diagnosis Population, 2009-2016 89

Table 107: Rosacea Therapeutics Market, Global, Prescription Population, 2001-2009 90

Table 108: Rosacea Therapeutics Market, Global, Prescription Population, 2009-2016 90

Table 109: Rosacea Therapeutics Market, Global, Usage Patterns, 2001-2009 91

Table 110: Rosacea Therapeutics Market, Global, Usage Patterns, 2009-2016 91

Table 111: Rosacea Therapeutics – Clinical Pipeline, 2009 93

Table 112: Dermatology Therapeutics Market, Global, Market Drivers, 2008 95

Table 113: Dermatology Therapeutics Market, Global, Market Restraints, 2008 96

Table 114: Dermatology Therapeutics Market, Global, Phase I Pipeline, 2009 113

Table 115: Dermatology Therapeutics Market, Global, Phase II Pipeline, 2009 118

Table 116: Dermatology Therapeutics Market, Global, Phase III Pipeline, 2009 133

Table 117: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2002-2009 149

Table 118: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 1998-2009 150

Table 119: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stages, 1998-2008 152

Table 120: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stages, 2002-2008 153

Table 121: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stages, 2001-2009 154

1.2 List of Figures

Figure 1: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 13

Figure 2: Dermatology Therapeutics Market, Global, Diseased Population, 2001-2016 14

Figure 3: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 15

Figure 4: Dermatology Therapeutics Market, Global, Diagnosis Population, 2001-2016 16

Figure 5: Dermatology Therapeutics Market, Global, Prescription Population, 2001-2016 17

Figure 6: Dermatology Therapeutics Market, Global, Usage Patterns, 2001-2016 18

Figure 7: Dermatology Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2001-2016 19

Figure 8: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2001-2016 20

Figure 9: Dermatology Therapeutics Market, The US, Diseased Population, 2001-2016 21

Figure 10: Dermatology Therapeutics Market, The US, Treatment Seeking Population, 2001-2016 22

Figure 11: Dermatology Therapeutics Market, The US, Diagnosis Population, 2001-2016 23

Figure 12: Dermatology Therapeutics Market, The US, Prescription Population, 2001-2016 24

Figure 13: Dermatology Therapeutics Market, The US, Usage Patterns, 2001-2016 25

Figure 14: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2001-2016 27

Figure 15: Dermatology Therapeutics Market, Europe, Diseased Population, 2001-2016 28

Figure 16: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2001-2016 29

Figure 17: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2001-2016 30

Figure 18: Dermatology Therapeutics Market, Europe, Prescription Population, 2001-2016 31

Figure 19: Dermatology Therapeutics Market, Europe, Usage Patterns, 2001-2016 32

Figure 20: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2001-2016 34

Figure 21: Dermatology Therapeutics Market, Japan, Diseased Population, 2001-2016 35

Figure 22: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016 36

Figure 23: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2001-2016 37

Figure 24: Dermatology Therapeutics Market, Japan, Prescription Population, 2001-2016 38

Figure 25: Dermatology Therapeutics Market, Japan, Usage Patterns, 2001-2016 39

Figure 26: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 42

Figure 27: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2016 43

Figure 28: Psoriasis Therapeutics Market, Global, Diseased Population, 2001-2016 44

Figure 29: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 45

Figure 30: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2001-2016 46

Figure 31: Psoriasis Therapeutics Market, Global, Prescription Population, 2001-2016 47

Figure 32: Psoriasis Therapeutics Market, Global, Usage Patterns, 2001-2016 49

Figure 33: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 57

Figure 34: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2001-2016 59

Figure 35: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2001-2016 60

Figure 36: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 61

Figure 37: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2001-2016 62

Figure 38: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2001-2016 63

Figure 39: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2001-2016 64

Figure 40: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 71

Figure 41: Acne Therapeutics Market, Global, Diseased Population, 2001-2016 73

Figure 42: Acne Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 74

Figure 43: Acne Therapeutics Market, Global, Diagnosis Population, 2001-2016 75

Figure 44: Acne Therapeutics Market, Global, Prescription Population, 2001-2016 76

Figure 45: Acne Therapeutics Market, Global, Usage Patterns, 2001-2016 77

Figure 46: Acne Therapeutics Market, Clinical Pipeline by Phase, 2009 78

Figure 47: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 84

Figure 48: Rosacea Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2016 85

Figure 49: Rosacea Therapeutics Market, Global, Diseased Population, 2001-2016 86

Figure 50: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 87

Figure 51: Rosacea Therapeutics Market, Global, Diagnosis Population, 2001-2016 88

Figure 52: Rosacea Therapeutics Market, Global, Prescription Population, 2001-2016 89

Figure 53: Rosacea Therapeutics Market, Global, Usage Patterns, 2001-2016 90

Figure 54: Rosacea Therapeutics – Clinical Pipeline by Drug Development Phase, 2009 92

Figure 55: Dermatology Therapeutics Market, Global, Market Indicators, 2009 95

Figure 56: Dermatology Therapeutics Market, Global, Key Market Events, 2008-2015 97

Figure 57: Dermatology Therapeutics Market, Global, Leading Companies, 2009 98

Figure 58: Dermatology Therapeutics Market, Global, Pipeline by Phase, 2009 112

Figure 59: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Indication, 2009 147

Figure 60: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Clinical Trial Phase, 2009 147

Figure 61: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Geography, 2009 148

Figure 62: GBI Research Methodology, 2010 161

Figure 63: GBI Research Market Forecasting Methodology, 2010 164

Companies mentioned

GlaxoSmithKline plc (GSK)

Johnson & Johnson

Bayer AG

Merck & Co., Inc

Novartis AG

Sanofi-Aventis

LEO Pharma A/S

F. Hoffmann-La Roche Ltd

L'Oreal

Galderma S.A.

Nestle S.A.

To order this report:

Healthcare Industry: The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker